| Title |
Management of psychosis in patients with Alzheimer’s disease: focus on aripiprazole
|
|---|---|
| Published in |
Clinical Interventions in Aging, September 2008
|
| DOI | 10.2147/cia.s3351 |
| Pubmed ID | |
| Authors |
Subramanian Madhusoodanan, Payal Shah |
| Abstract |
Psychosis of Alzheimer's disease (AD) is characterized by delusions or hallucinations and may be associated with agitation, negative symptoms or depression. There are no psychotropic medications that are approved by the US FDA for the treatment of psychosis of AD. However, atypical antipsychotics have been widely used and recommended by geriatric experts in the management of psychosis of AD in view of the modest efficacy and relative safety until FDA warnings were issued in 2005 and meta-analytic studies showed no significant difference to placebo. The FDA warnings on the cardiac, metabolic, cerebrovascular, and mortality risks have caused serious concerns for the use of atypical antipsychotic agents in elderly patients with dementia. Only a few studies have evaluated prospectively the effects of aripiprazole in psychosis associated with AD. These studies show improvement in the symptoms of psychosis associated with AD with aripiprazole. The safety and tolerability profile of aripiprazole suggests a low potential for negative impact on dementia and overall patient health. Further studies comparing the efficacy and tolerability of aripiprazole vs other atypical antipsychotics in dementia are needed. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 1 | 2% |
| Unknown | 61 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 12 | 19% |
| Researcher | 9 | 15% |
| Student > Ph. D. Student | 8 | 13% |
| Other | 7 | 11% |
| Student > Postgraduate | 5 | 8% |
| Other | 11 | 18% |
| Unknown | 10 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 29% |
| Psychology | 10 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 11% |
| Neuroscience | 3 | 5% |
| Nursing and Health Professions | 3 | 5% |
| Other | 8 | 13% |
| Unknown | 13 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 January 2014.
All research outputs
#8,262,107
of 25,374,647 outputs
Outputs from Clinical Interventions in Aging
#794
of 1,968 outputs
Outputs of similar age
#34,418
of 95,712 outputs
Outputs of similar age from Clinical Interventions in Aging
#6
of 13 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one has received more attention than most of these and is in the 66th percentile.
So far Altmetric has tracked 1,968 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.1. This one has gotten more attention than average, scoring higher than 58% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 95,712 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.